$IKT Inhibikase is leading the fight against Parki
Post# of 711
(Total Views: 105)
Posted On: 07/01/2021 1:37:13 PM
$IKT Inhibikase is leading the fight against Parkinson's Disease and other very serious disorders with advanced new products that are showing great promise.
From the company website:
IkT-148009 for Parkinson’s Disease
Our lead small-molecule product candidate, IkT-148009, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that targets underlying disease mechanisms to halt the progression and reverse functional loss of Parkinson’s disease in the brain and the GI complications of Parkinson’s disease. We believe that IkT-148009 is the only disease-modifying drug in development for Parkinson’s disease that is focused on a clinically validated target and that IkT-148009 has the potential to be the first disease-modifying therapy for Parkinson’s disease that blocks a checkpoint on the pathway that drives Parkinson’s disease progression.
ABOUT IKT-148009
First-in-class Therapy to Reverse the Course of Parkinson’s Disease
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in the brain and GI tract in animal models using IkT-148009, we submitted two Investigational New Drug (IND) applications in February, 2019, to begin clinical development in multiple classes of Parkinson’s patients. Clinical development should proceed through 2024.
About Inhibikase (http://www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently completing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
From the company website:
IkT-148009 for Parkinson’s Disease
Our lead small-molecule product candidate, IkT-148009, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that targets underlying disease mechanisms to halt the progression and reverse functional loss of Parkinson’s disease in the brain and the GI complications of Parkinson’s disease. We believe that IkT-148009 is the only disease-modifying drug in development for Parkinson’s disease that is focused on a clinically validated target and that IkT-148009 has the potential to be the first disease-modifying therapy for Parkinson’s disease that blocks a checkpoint on the pathway that drives Parkinson’s disease progression.
ABOUT IKT-148009
First-in-class Therapy to Reverse the Course of Parkinson’s Disease
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in the brain and GI tract in animal models using IkT-148009, we submitted two Investigational New Drug (IND) applications in February, 2019, to begin clinical development in multiple classes of Parkinson’s patients. Clinical development should proceed through 2024.
About Inhibikase (http://www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently completing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
(0)
(0)Scroll down for more posts ▼